Abstract
Peripheral blood lymphocytes from patients with multiple sclerosis were studied for their ability to lyse target cells infected with measles virus using a 51Cr release assay. Immune-specific cytolysis caused by lymphocytes from patients in remission was equivalent to cytolysis observed with lymphocytes from normal immune subjects in both the absence and the presence of added anti-measles virus antibodies. The ability of any individual patient's lymphocytes to kill measles virus-infected targets did not significantly change as the patients' clinical course fluctuated from remission to exacerbation. In addition, sera from multiple sclerosis patients and normal subjects invariably enhanced cytolysis, and no blocking of lymphocyte-mediated killing was observed.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
